Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Intraday Rise 5.62% in Regular Trading, Raised Full-Year Revenue Guidance After Strong Third-Quarter Results

Market Focus11-05

On November 5, BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS recorded an Intraday Rise of 5.62% in Regular Trading, trading at $400.5851 with turnover of $74.3225 million.

The clearest catalyst was a same-day earnings and guidance update: the company reported third-quarter revenue growth and raised its full-year revenue outlook, reinforcing momentum already supported by an FDA priority review decision for a Brukinsa combination regimen.

The company said first-nine-month revenue reached RMB 34.993 billion, up 26.8% year over year, while net profit attributable to shareholders rose 431.8% to RMB 6.055 billion. It also said third-quarter revenue grew 34% year over year and lifted expected full-year revenue to RMB 46.3 billion-RMB 47.0 billion from RMB 44.9 billion-RMB 46.2 billion previously; revenue less operating cost and expenses is expected at RMB 8.4 billion-RMB 9.0 billion. Earlier in the day, it also disclosed that the FDA granted priority review to a supplemental application for Brukinsa plus rituximab in first-line adult mantle cell lymphoma, based on phase 3 data showing a 43% reduction in disease progression or death risk versus a standard chemoimmunotherapy regimen.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment